Montreal (Canada), July 31, 2019 – PENDOPHARM, a division of Pharmascience Inc., headquartered in Montreal, Canada, announced today the launch in Canada of ELEVIEW™. ELEVIEW™ is the first all-in-one submucosal injectable composition intended for use in endoscopic resection procedures for submucosal lift of polyps, adenomas or other gastrointestinal (GI) mucosal lesions in the colon, prior to excision with a snare or endoscopic device.1
ELEVIEW™ is designed to elevate the mucosal layer and the tissue to be excised from the submucosal and the external muscular layer, providing a submucosal cushion of optimal height and duration, allowing the endoscopist an easier and safer resection procedure: endoscopic mucosal resection (EMR), hybrid EMR and endoscopic submucosal dissection (ESD).
ELEVIEW™ does not require any special apparatus or equipment, and it is designed to be used with the most common endoscopic resection devices.
ELEVIEW™ is in stock and available through pharmaceutical distributors and medical device hospital distribution channels.
“Pendopharm is thrilled to expand its presence in and reaffirm its commitment to GI and endoscopy with such innovative solutions as ELEVIEWTM, the first-ever product indicated for submucosal lift of polyps and adenomas in Canada.” said Jean-Francois Lemieux, Vice-President & General Manager of Pendopharm, a division of Pharmascience Inc.
“Approval from Health Canada further expands the geographic reach of this innovative product, providing this new market with an important tool to assist in the removal of mucosal lesions during an endoscopic procedure.” said Alessandro Della Chà, CEO of Cosmo Pharmaceuticals.
Pendopharm is a division of Pharmascience Inc., a Canadian privately-owned company. Established in 1983, Pharmascience Inc. is the largest pharmaceutical company in Quebec, with a highly-skilled workforce of 1,600 people. It commercializes nearly 300 products, including branded prescription, OTC and BTC products as well as generic products in Canada and with its affiliates and distributors in Europe, Asia, Middle East, Africa and Oceania.
Strategically committed to growth, Pendopharm is actively engaged in licensing, partnering, developing and marketing specialty prescription medicines as well as consumer brands.
About Cosmo Pharmaceuticals
Cosmo is a specialty pharmaceutical company focused in treating selected Gastrointestinal Disorders and Endoscopy. The Company’s proprietary clinical development pipeline specifically addresses innovative treatments for IBD, Colonic Infections and detection of colonic lesions.
For additional information on Cosmo and its products please visit the Company’s website: www.cosmopharma.com
For further information:
Senior Brand Manager
PENDOPHARM, a division of Pharmascience Inc.
Tel: (514) 927-2645
ELEVIEW and the ELEVIEW logo are trademarks of the Cosmo Pharmaceuticals group of companies and are used under license by PENDOPHARM, a division of Pharmascience Inc.
1. ELEVIEW™ Product Information. Pendopharm, Division of Pharmascience, Inc. April 2019.
Cosmo Technologies Ltd.
Riverside II, Sir John Rogerson’s Quay
Dublin 2, Ireland
Pendopharm, Division of Pharmascience Inc.
Montreal, Canada, H4P 2T4